This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutTALZENNA MoATalzenna MoAgBRCA testingIdentifying patientsGuidelinesStudy designStudy designBaseline characteristicsEfficacy & SafetyTALZENNA efficacyPrimary endpoint & subgroup analysisSecondary endpoints: ORRSecondary endpoint: OSExploratory endpoints: DoR & TTRTALZENNA safetySafety and tolerabillityAdverse eventsHaematologic/Nonhaematologic AEsPatient-reported outcomes with TALZENNAPatient-reported outcomesGHS/QoLBreast symptomsDosingDosingDose recommendation and special populationsDose modifications/managementPatient ProfilesSupport & ResourcesSupport & ResourcesMaterialsVideosElevateElevatePersonalising Breast Cancer TreatmentUnderstanding and Optimising PARP Inhibitors for mBCPARP Inhibitors in mBC: the role of Real World Evidence
Manageable safety and tolerability with TALZENNA vs chemotherapy1,2Adverse events* (in ≥20% in patients receiving TALZENNA) in EMBRACA3,4
Scroll left to view table
Adverse reactions TALZENNA n=286 (%) Chemotherapy n=126 (%)
Grade 3 Grade 4 Grades
Grade 3 Grade 4
Blood and lymphatic system disorders
Anaemia​​​​​​​ 53 39 1 18 4 1
Neutropenia§ 35 18 3 43 20 15
Thrombocytopenia|| 27 11 4 7 2 0
Metabolism and nutrition disorders
Decreased appetite 21 <1 0 22 1 0
Nervous system disorders
Headache 33 2 0 22 1 0
Gastrointestinal disorders
Nausea 49 <1 0 47 2 0
Vomiting 25 2 0 23 2 0
Diarrhea 22 1 0 26 6 0
Skin and subcutaneous tissue disorders
Alopecia 25 N/A N/A 28 N/A N/A
General disorders and administration site conditions
Fatigue 50 2 0 43 3 0
Adapted from Litton et al. N Engl J Med (suppl appendix). 2018.1Special Warnings and Precautions for TALZENNA5Myelosuppression5

Myelosuppression consisting of anaemia, leukopenia/neutropenia, and/or thrombocytopenia have been reported in patients treated with TALZENNA. TALZENNA should not be started until patients have recovered from haematological toxicity caused by previous therapy (≤Grade 1).
Precautions should be taken to routinely monitor haematology parameters and signs and symptoms associated with anaemia, leukopenia/neutropenia, and/or thrombocytopenia in patients receiving TALZENNA. If such events occur, dose modifications (reduction or interruption) are recommended (refer to full SmPC or Dosing section). Supportive care with or without blood and/or platelet transfusions and/or administration of colony stimulating factors may be used as appropriate.

Myelodysplastic syndrome/Acute Myeloid Leukemia5

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) have been reported in patients who received TALZENNA. Overall, MDS/AML has been reported in <1% (3 out of 787, 0.4%) of solid tumor patients treated with TALZENNA in clinical studies. The duration of TALZENNA treatment in these three patients prior to developing MDS/AML was 4 months, 24 months, and 60 months respectively. These patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. 

TALZENNA should not be started until patients have adequately recovered from haematological toxicity caused by previous chemotherapy. 

Complete blood count should be obtained prior to starting Talzenna therapy and monitored monthly and as clinically indicated.

AE=adverse event; CTCAE=Common Terminology Criteria for Adverse Events; N/A=not applicable; NCl=National Cancer Institute; PARP=poly (ADP-ribose) polymerase; PFS=progression-free survival.Graded according to NCI CTCAE 4.03.Capecitabine, eribulin, gemcitabine, or vinorelbine.​​​​​​​Includes anaemia and decreased hemoglobin level.Includes neutropenia, decreased neutrophil count, and neutropenic sepsis. 
lncludes thrombocytopenia and decreased platelet count.Alopecia Grade 1: 23% with TALZENNA vs 20% with chemotherapy; Grade 2: 2% with TALZENNA vs 8% with chemotherapy. Grade 1 defined as hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection. A different hairstyle may be required to cover the hair loss, but it does not require a wig or hairpiece to camouflage. Grade 2 defined as hair loss of ≥50% of normal for that individual that is readily apparent to others. A wig or hairpiece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact.
Explore more Adverse events
References:Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.Hurvitz SA, Gonҫalves A, Rugo HS, et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial. Oncologist. 2019;24:1-12.Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation (supplementary appendix). N Engl J Med. 2018;379(8):753-763.National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: National Institutes of Health. Revised June 2010, version 4.03. NIH publication 09-5410.TALZENNA Summary of Product Characteristics. 
​​​​​​​ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of full SmPC for how to report adverse reactions.

Legal Category: S1A 
Further information is available upon request

PP-TAL-IRL-0061 April 2023
TALZENNA safety Significantly longer PFS

Superior to chemotherapy in delaying disease progression5

See the data 
Convenient, once-daily oral dosing

One dose once a day with or without food5

Learn more
TALZENNA Summary of Product Characteristics Product CharacteristicsLoading

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024